Should COVID-19 be branded to viral thrombotic fever?

Should COVID-19 be branded to viral thrombotic fever?

Coronaviruses can cause a diverse array of clinical manifestations, from fever with symptoms of the common cold to highly lethal severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). SARS-CoV-2, the coronavirus discovered in Hubei province, China, at the end of 2019,...

Full description

Bibliographic Details
Main Authors:	Rubens Carmo Costa-Filho, Hugo Caire Castro-Faria Neto, José Mengel, Marcelo Pelajo-Machado, Marco Aurélio Martins, Érica Távora Leite, Hugo Tannus Mendonça-Filho, Tatiana de Arruda Campos Brasil de Souza, Gonzalo Bentacor Bello, José Paulo Gagliardi Leite
Format:	Article
Language:	English
Published:	Fundação Oswaldo Cruz (FIOCRUZ) 2021-04-01
Series:	Memorias do Instituto Oswaldo Cruz
Subjects:	endothelium COVID-19 SARS-CoV-2 SARS CoV Mpro inflammation coagulation hypercoagulability thrombosis thromboelastometry
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762021000100850&tlng=en

Similar Items

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase
by: Muhammad Usman Mirza, et al.
Published: (2020-08-01)

Appraisals of the Bangladeshi Medicinal Plant Calotropis gigantea Used by Folk Medicine Practitioners in the Management of COVID-19: A Biochemical and Computational Approach
by: Mycal Dutta, et al.
Published: (2021-05-01)

Screening for Active Compounds of <i>Acorus calamus</i> against SARS-CoV-2 Viral Protease and Mechanism Prediction
by: Yuting Huang, et al.
Published: (2024-03-01)

Effect of chitooligosaccharide on the inhibition of SARS-CoV-2 main protease
by: Qian Wang, et al.
Published: (2023-02-01)

Docking and Dynamics Study of Phytochemicals as Potent Inhibitors against SARS-CoV-2 Main Protease
by: Palla Ramprasad, et al.
Published: (2022-12-01)

The importance of good practices and false hits for QSAR-driven virtual screening real application: a SARS-CoV-2 main protease (Mpro) case study
by: Mateus Sá Magalhães Serafim, et al.
Published: (2023-07-01)

Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19
by: Karol Biernacki, et al.
Published: (2024-12-01)

A Tale of Two Proteases: M<sup>Pro</sup> and TMPRSS2 as Targets for COVID-19 Therapies
by: Barbara Farkaš, et al.
Published: (2023-06-01)

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?
by: Srijan Chatterjee, et al.
Published: (2023-06-01)

Discovery and evaluation of active compounds from Xuanfei Baidu formula against COVID-19 via SARS-CoV-2 Mpro
by: Min Zhang, et al.
Published: (2023-08-01)

Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
by: Julia M Flynn, et al.
Published: (2022-06-01)

Developing evolution-resistant drugs for COVID-19
by: Daniel M Weinreich
Published: (2022-07-01)

Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
by: Matteo Pavan, et al.
Published: (2022-12-01)

In Silico Design of Peptide-Based SARS-CoV-2 Fusion Inhibitors That Target WT and Mutant Versions of SARS-CoV-2 HR1 Domains
by: Shana V. Stoddard, et al.
Published: (2021-07-01)

The Endothelium and COVID-19: An Increasingly Clear Link Brief Title: Endotheliopathy in COVID-19
by: Isabelle Six, et al.
Published: (2022-05-01)

Sinus venous thrombosis as a complication of COVID-19-associated hypercoagulability
by: Sinda Zarrouk, et al.
Published: (2021-09-01)

Promising Antiviral Activities of Natural Flavonoids against SARS-CoV-2 Targets: Systematic Review
by: Ridhima Kaul, et al.
Published: (2021-10-01)

SARS-CoV-2, the other face to SARS-CoV and MERS-CoV: Future predictions
by: T.M. Abdelghany, et al.
Published: (2021-03-01)

Chemokine Regulation During Epidemic Coronavirus Infection
by: Shamik Majumdar, et al.
Published: (2021-02-01)

Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness
by: John A. Lednicky, et al.
Published: (2021-07-01)

Alantolactone: A Potential Multitarget Drug candidate for Prevention of SARS-CoV-2 Cell Entry
by: Erum Zafar, et al.
Published: (2022-12-01)

Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
by: Jonathan T. Lee, et al.
Published: (2022-08-01)

Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19
by: Hayate Javed, et al.
Published: (2021-02-01)

Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture
by: Khushboo Bafna, et al.
Published: (2021-05-01)

POTENTIAL RISK OF BRAIN DAMAGE AND POOR DEVELOPMENTAL OUTCOMES IN CHILDREN PRENATALLY EXPOSED TO SARS-COV-2: A SYSTEMATIC REVIEW
by: Marcio Leyser, et al.
Published: (2021-05-01)

Potential Immunogenic Activity of Computationally Designed mRNA- and Peptide-Based Prophylactic Vaccines against MERS, SARS-CoV, and SARS-CoV-2: A Reverse Vaccinology Approach
by: Taimoor Khan, et al.
Published: (2022-04-01)

Human Coronavirus Spike Protein Based Multi-Epitope Vaccine against COVID-19 and Potential Future Zoonotic Coronaviruses by Using Immunoinformatic Approaches
by: Zulqarnain Baloch, et al.
Published: (2022-07-01)

Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans
by: Sicong Yu, et al.
Published: (2021-06-01)

Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
by: Chunting He, et al.
Published: (2020-07-01)

EMERGENCIA DE SARS-COV-2. ASPECTOS BÁSICOS SOBRE SU ORIGEN, EPIDEMIOLOGÍA, ESTRUCTURA Y PATOGENIA PARA CLÍNICOS
by: Jeannette Dabanch
Published: (2021-01-01)

Recent Chronology of COVID-19 Pandemic
by: Sazada Siddiqui, et al.
Published: (2022-05-01)

The interplay between emerging human coronavirus infections and autophagy
by: Zhenyu Zhao, et al.
Published: (2021-01-01)

Data mining of coronavirus: SARS-CoV-2, SARS-CoV and MERS-CoV
by: Jung Eun Huh, et al.
Published: (2021-04-01)

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections
by: Yun-yu Zhang, et al.
Published: (2020-08-01)

Comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’
by: Ethan S FitzGerald, et al.
Published: (2022-01-01)

SARS-CoV-2 mutations on diagnostic gene targets in the second wave in Zimbabwe: A retrospective genomic analysis
by: C Nyagupe, et al.
Published: (2023-03-01)

Mechanistic insights of host cell fusion of SARS-CoV-1 and SARS-CoV-2 from atomic resolution structure and membrane dynamics
by: Chakraborty, Hirak, et al.
Published: (2021)

An understanding of coronavirus and exploring the molecular dynamics simulations to find promising candidates against the Mpro of nCoV to combat the COVID-19: A systematic review
by: Madhur Babu Singh, et al.
Published: (2022-11-01)

Identification of SARS-CoV-2 Main Protease Inhibitors Using Chemical Similarity Analysis Combined with Machine Learning
by: Karina Eurídice Juárez-Mercado, et al.
Published: (2024-02-01)

The Multisystem Impact of Long COVID: A Comprehensive Review
by: Nicoleta Negrut, et al.
Published: (2024-01-01)